AzTrials
AzTrials

CancerECO 2NCT07390045

Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors

A study testing EXCAP, MAAT and ECO in people with Cancer, run by University of Rochester at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The objective of this study is to assess the preliminary effects of an integrated exercise and cognitive rehabilitation intervention (ECO), an exercise intervention (EXCAP), and a cognitive rehabilitation intervention (MAAT) as compared to usual care on objective cognition (Trail Making Test). Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Cancer
What is being tested?
EXCAP, MAAT and ECO
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteUnited States
Study dates
11 May 2026to 31 Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Age ≥65 years (from date of consent, confirmed on the electronic medical record)
  • A diagnosis of any cancer
  • Have completed curative intent treatments
  • Patients on endocrine therapies are allowed to enroll
  • Patients with hematologic malignancies after autologous or allogeneic stem cell transplant are allowed to enroll if they have completed curative-intent treatment
  • Answered "yes" to the verbal question "Do you have concerns about memory or other thinking abilities following your cancer treatment?"
Show all 12Show fewer
  • Able to speak English (interventions are available in English only)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3#
  • No medical contraindications to exercise#
  • Able to walk 4 meters#
  • Able to provide informed consent#
  • Confirmed through eligibility confirmation with the patient's oncologist or their designee

Who cannot join

  • Any physical, psychological, or social impairments that would interfere with a patient's ability to participate in the study as determined by the patient's oncologist or their designee
  • Unwilling to complete study procedures

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • University of Rochester

    Rochester, New York, 14642

    Kah Poh Loh, 585-276-4353, Kahpoh_Loh@URMC.Rochester.edu

    Recruiting

Other trials in United States

About this study

Official title: Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors: A Pilot Randomized Controlled Trial

The objective of this study is to assess the preliminary effects of an integrated exercise and cognitive rehabilitation intervention (ECO), an exercise intervention (EXCAP), and a cognitive rehabilitation intervention (MAAT) as compared to usual care on objective cognition (Trail Making Test).

Read the detailed description

Cancer-Related Cognitive Dysfunction (CRCD) is a prevalent problem for older cancer survivors. Sixty-four percent of current cancer survivors are aged ≥65, and by 2040, it is estimated that over 19 million older cancer survivors will be living in the United States. Up to 50% of these individuals experience CRCD post-treatment, which can persist for years after treatment completion. For older adults, CRCD can affect their ability to perform daily tasks, such as taking medications or managing finances, reducing their overall independence. Although evidence-based interventions exist to treat CRCD, older adults were underrepresented in these trials, despite them being most at risk for CRCD and its consequences. The National Cancer Institute, topic experts, and patient advocates have highlighted the urgent need for accessible interventions to address CRCD symptoms, particularly for older adults.

Exercise for Cancer Patients (EXCAP) is an individually tailored, low-to-moderate intensity, home-based walking and progressive resistance exercise program designed for patients with cancer delivered by an exercise physiologist. The Investigators adapted EXCAP for digital health applications, allowing the tracking of exercise adherence, barriers to exercise, and symptoms. In a large randomized controlled trial (RCT), EXCAP improved patient-reported cognition compared to usual care. In older adults with cancer, EXCAP patients demonstrated improvements in cognitive impairment, as assessed via the Trail-Making Test, which evaluates processing speed.

Memory and Attention Adaptation Training (MAAT) was previously shown to improve CRCD and psychological function in three clinical trials. The Investigators tailored aspects for the particular needs of older adults, including support for telehealth delivery. The intervention, based on cognitive behavioral therapy principles, integrates cognitive rehabilitation skills and provides education and training in adaptive behavioral coping skills, stress management techniques, and compensation strategies to address CRCD. MAAT is standardized via a manual and delivered one-on-one via video-conferencing over 10 weekly workshops by a trained clinician. In a pilot RCT, MAAT improved perceived cognition [Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) and objective cognition (e.g., processing speed). In a separate study of 34 older adults with cancer, improvements from baseline to post-intervention were observed in objective cognitive measures and perceived cognition.

Exercise and Cognition (ECO) leverages the synergy between EXCAP and MAAT, and enhances both general and exercise self-efficacy, improves adherence, and promotes lasting behavior change for sustained cognitive benefits. Adapted with input from the patient advisory board, ECO is a 12-week program delivered virtually by an exercise physiologist and a trained clinician, facilitated through digital health applications. Delivering both interventions simultaneously was evaluated in a single-arm pilot study of eight older adults with cancer who had completed curative treatments and were experiencing residual CRCD symptoms. Preliminary results suggest greater self-efficacy and exercise adherence. From baseline to post-intervention, all patients reported clinically meaningful improvements in FACT-Cog; these improvements were greater than those observed with EXCAP or MAAT intervention alone.

However, it is unknown which behavioral intervention is most effective at addressing CRCD symptoms. It is also unknown which type of CRCD intervention is the "best fit" for each patient. To inform the design of a future R01-funded definitive RCT to fill these gaps, the Investigators need to obtain more precise estimates of ECO's effects and identify the most appropriate comparison arms.

Conditions
Cancer
Being tested
EXCAP, MAAT, ECO
Keywords
geriatric oncology, cancer survivors, exercise, cognitive rehabilitation, cognition
Medical subject headings
Neoplasms, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EXCAPBehavioural

    The first component of the EXCAP exercise program is an individually tailored walking prescription and provides low to moderately intense aerobic exercise [5-8 exercise rating of perceived exertion on the American College of Sports Medicine (ACSM) revised rating scale, which is a visual analog scale ranging from 1 = "Not tired at all" to 10 = "So tired, I can't go anymore"] 7 days a week. This walking prescription will be developed and individually tailored for each patient based on step data reported by the patient. A Garmin activity tracker (a wearable sensor-based device) will be used to record the number of steps they walk daily during the 4-7 day baseline assessment. Patients will report their steps daily on a paper form, electronically via REDCap, or over the phone to the study staff at the end of the 4-7 day baseline assessment period. Alternatively, steps can also be obtained via the activity tracker by study staff.

  • MAATBehavioural

    The MAAT intervention consists of 10 manualized workshops that will be delivered by a trained clinician. Patients will be provided with a workbook for skills practice in between sessions. A summary of workshop content is provided in Table 1.

    During Workshop #2, study staff or a trained clinician will provide patients with a link to a Vimeo video through the app. The Vimeo video has been created by the study team and guides patients through relaxation strategies to use before stressful events. Patients will be able to access the video without providing any personal information to the website.

  • ECOBehavioural

    Patients will receive the integrated EXCAP and MAAT interventions.

Study groups in NCT07390045
Study groupRoleWhat they receive
Exercise for Cancer Patients (EXCAP; Intervention)ExperimentalExercise for Cancer Patients (EXCAP) is an individually tailored, low-to-moderate intensity, home-based walking and progressive resistance exercise program designed for patients with cancer delivered by an exercise physiologist. It also includes digital health applications, allowing the tracking of exercise adherence, barriers to exercise, and symptoms.
Receives: Behavioral: EXCAP
Memory and Attention Adaptation Training (MAAT; Intervention)ExperimentalMemory and Attention Adaptation Training (MAAT) is an intervention based on cognitive behavioral therapy principles that integrates cognitive rehabilitation skills and provides education and training in adaptive behavioral coping skills, stress management techniques, and compensation strategies to address CRCD.
Receives: Behavioral: MAAT
Usual CareNo interventionPatients in the control group will receive care as usual.
Exercise and Cognition (ECO; Intervention)ExperimentalPatients will receive the integrated EXCAP and MAAT interventions.
Receives: Behavioral: ECO

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective cognition

    Trail Making Test A \& B: The Trail Making Test assesses sustained attention. The Written Trail Making Test A \& B is preferred; however, if this is not feasible, the oral Trail Making Test will be utilized. There is not a range, lower scores indicating better performance

    Measured: Change from baseline to week 12

Secondary outcomes (3)
  1. Perceived Cognition

    Functional Assessment of Cancer Therapy-Cognition Perceived Cognitive Abilities. Scores range from 0-28, higher scores are better.

    Measured: Change from baseline to week 12

  2. Depressive symptoms

    Center for Epidemiological Studies Depression Scale (CES-D): The CES-D is a 20-item depression scale developed and validated for use with various populations. Scores range from 0-60, higher scores are worst.

    Measured: Change from baseline to week 12

  3. Anxiety symptoms

    General Anxiety Disorder-7 (GAD-7): GAD-7 is a 7-item screening tool for anxiety. Scores range from 0-21, higher scores are worst.

    Measured: Change from baseline to week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2026
  2. Study start11 May 2026
  3. Primary completion31 Mar 2028 (estimated)
  4. Study completion31 Mar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07390045
Sponsor's protocol ID
UOCPC26001
Acronym
ECO 2
Status last verified
Jul 2026
First submitted
28 Jan 2026
Last updated
10 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified data will be shared with other investigators if requested. Published papers will be made available in portable document format.

Publications

  • Loh KP, Sanapala C, Watson EE, Jensen-Battaglia M, Janelsins MC, Klepin HD, Schnall R, Culakova E, Vertino P, Susiarjo M, Lin PJ, Mendler JH, Liesveld JL, Huselton EJ, Taberner K, Mohile SG, Mustian K. A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms. Blood Adv. 2022 Jul 12;6(13):3850-3860. doi: 10.1182/bloodadvances.2022007056.

    PubMed 35320340
  • Loh KP, Sanapala C, Janelsins M, Klepin HD, Schnall R, Culakova E, Sohn MB, Vertino P, Susiarjo M, Jensen-Battaglia M, Becker MW, Liesveld J, Mendler JH, Huselton E, Lin PJ, Mustian K. Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2). J Geriatr Oncol. 2022 May;13(4):545-553. doi: 10.1016/j.jgo.2021.12.011. Epub 2021 Dec 21.

    PubMed 34949540

Questions about this trial

What is this clinical trial studying?

A study testing EXCAP, MAAT and ECO in people with Cancer, run by University of Rochester at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kah Poh Loh (585-276-4353, Kahpoh_Loh@URMC.Rochester.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective cognition (time frame: Change from baseline to week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07390045, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in